<DOC>
	<DOCNO>NCT00745433</DOCNO>
	<brief_summary>This study conduct Europe . The aim observational study investigate efficacy ( e.g . glycemic control ) safety ( e.g . hypoglycemic episode ) add repaglinide monotherapy metformin type 2 diabetic patient normal clinical practice</brief_summary>
	<brief_title>Switch From Metformin Monotherapy Bitherapy With Metformin Repaglinide</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus , Type 2</mesh_term>
	<mesh_term>Repaglinide</mesh_term>
	<mesh_term>Metformin</mesh_term>
	<criteria>Type 2 diabetes Metformin monotreatment HbA1c great 7 % Treatment accord SPC Informed consent obtain Any contraindication use repaglinide ( accord SPC )</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2016</verification_date>
</DOC>